© 1999 by European Society of Cardiology
The North American experience with the Ablate and Pace Trial (APT) for medically refractory atrial fibrillation
aMedical College of Virginia Richmond, Virginia; bUniversity of Alabama at Birmingham Birmingham, Alabama, U.S.A.
The Ablate and Pace Trial (APT) was a prospective registry study of clinical outcomes and survival following ablation and pacing therapy for medically refractory atrial fibril-lation. One hundred and fifty-six patients were enrolled at 16 centres in North America. The mean patient age was 66±11 years, with mean left ventricular ejection fraction of 48%±18%. Seventy-eight percent of the patients had structural heart disease.
During one year of follow up, multiple measures of quality-of-life showed significant and sustained improvement following ablation and pacing therapy. Also, left ventricular ejection increased significantly for patients with baseline left ventricular ejection fraction <45%. Metabolic exercise testing showed trends toward improved exercise tolerance; however, these did not achieve statistical significance. The one year overall survival was 85%, with 3% of patients experiencing sudden death.
In summary, this large, non-randomized, trial showed significant improvement in quality of life and left ventricular function following ablation and pacing therapy. Ablation and pacing therapy is a viable strategy for palliative management of patients with medically refractory, highly symptomatic atrial fibrillation.
Key Words: Atrial fibrillation, radiofrequency ablation, quality of life, left ventricular function
Correspondence: Mark A. Wood, MD, Box 980053, Medical College of Virginia, Richmond, VA 23298, U.S.A.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Stellbrink Heart rate, regularity, and synchronicity in heart failure: a tale of three brothers Eur. Heart J., April 1, 2005; 26(7): 637 - 638. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yamada, D. O. Martin, K. A. Mowrey, N. L. Greenberg, and D. W. Wallick Effects of coupled pacing on cardiac performance during acute atrial tachycardia and fibrillation: an old therapy revisited for a new reason Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2630 - H2638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S K S Lairikyengbam, M H Anderson, and A G Davies Present treatment options for atrial fibrillation Postgrad. Med. J., February 1, 2003; 79(928): 67 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Berkowitsch, T. Neumann, K. Kurzidim, C. Reiner, M. Kuniss, G. Siemon, J. Sperzel, and H. F. Pitschner Comparison of generic health survey SF-36 and arrhythmia related symptom severity check list in relation to post-therapy AF recurrence Europace, January 1, 2003; 5(4): 351 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Capucci, G.Q. Villani, N. Marrazzo, and M. Piepoli The complementary role of drug, ablation and device in the electrical therapy of atrial fibrillation Eur. Heart J. Suppl., November 1, 2001; 3(suppl_P): P47 - P52. [Abstract] [PDF]
|
|
|
|
|
|
M. Brignole, M. Gammage, L. Jordaens, R. Sutton, and on behalf of the Barcelona Discussion Group Report of a study group on ablate and pace therapy for paroxysmal atrial fibrillation Europace, January 1, 1999; 1(1): 8 - 13. [Abstract] [PDF]
|
|